MetaCap

Armata Pharmaceuticals (ARMP) vs Fate Therapeutics (FATE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fate Therapeutics (FATE) has outperformed Armata Pharmaceuticals (ARMP) over the past year, losing 10.8% versus a loss of 56.9%. Over five years, ARMP leads with a -42.0% price change compared with -98.3% for FATE. Armata Pharmaceuticals is the larger company by market cap ($112.7 million vs $111.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%FATE-10.78%
+215%+70%-75%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%FATE-98.36%
+246%+65%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus FATE key metrics
MetricARMPFATE
Share price$3.03$0.919
Market cap$112.69M$111.82M
1-day change+1.68%-9.01%
YTD return-51.75%-6.22%
1-year return-56.90%-10.78%
5-year return-41.95%-98.25%
EPS (TTM)$-4.17$-1.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.65M
Revenue growth (YoY)—-51.24%
Net income (latest FY)$-173.80M$-136.31M
Operating margin—-2222.45%
Net margin—-2051.08%
52-week high$14.98$3.23
52-week low$2.40$0.90
Distance from 52-week high-79.77%-71.55%
Analyst consensusnonebuy
Avg. price target upside+477.56%+522.42%
Average volume182.52K1.53M
Shares outstanding37.19M121.67M
Employees61161
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FATE has outperformed ARMP by 46.1 percentage points over the past year.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Fate Therapeutics

FATE stock →

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees

ARMP vs FATE FAQ

Which is bigger, Armata Pharmaceuticals or Fate Therapeutics?

Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $112.69M compared with $111.82M for Fate Therapeutics (FATE).

Which stock has performed better over the past year, ARMP or FATE?

FATE returned -10.78% over the past 12 months, compared with -56.90% for ARMP (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Fate Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons